Hematopoiesis
Return to Library
|
Free Hematopoiesis Articles |
|
|
|
|
Report summarizes myelodysplastic syndrome immunology study findings from H. Lee Moffitt Cancer Center
2009 JUL 27 - (NewsRx.com) -- A new study, 'Altered naive and memory CD4+ T-cell homeostasis and immunosenescence characterize younger patients with myelodysplastic syndrome,' is now available. "Response to immunosuppressive therapy (IST) in younger patients with myelodysplastic syndrome (MDS) has been linked to a T-cell-dominant autoimmune process that impairs hematopoiesis. Analysis of the age-adjusted CD4:CD8 ratio in 76 MDS patients compared with 54 healthy controls showed that inadequate CD4+, rather than expansion of CD8+ T cells, was associated with a lower ratio in a group that included both lower and higher risk MDS patients defined by the International Prognostic Scoring System," researchers in the United States report. "In younger MDS patients, naive and memory phenotypes defined by CD45RA and CD62L display showed depletion of naive CD4+ and CD8+ T cells, suggesting a possible relationship to IST responsiveness. To determine the correlation between T-cell subset distribution, T-cell turnover and autoimmunity, a cohort of 20 patients were studied before and after IST. The CD4:CD8 ratio correlated inversely with the proliferative T-cell index before treatment in IST-responsive patients, suggesting that proliferation may be linked to accelerated CD4+ T-cell turnover and hematopoietic failure. Our data show seminal findings that both CD4+ and CD8+ T-cell subsets are dysregulated in MDS," wrote J.X. Zou and colleagues, H. Lee Moffitt Cancer Center. The researchers concluded: "Association between these T-cell defects and response to IST suggests that aberrant T-cell homeostasis and chronic activation are critical determinants influencing autoimmune hematopoietic suppression in younger patients." Zou and colleagues published their study in Leukemia (Altered naive and memory CD4+ T-cell homeostasis and immunosenescence characterize younger patients with myelodysplastic syndrome. Leukemia, 2009;23(7):1288-96). For additional information, contact J.X. Zou, Immunology Program at the H Lee Moffitt Cancer Center, Tampa, FL 33612 USA.. Publisher contact information for the journal Leukemia is: Nature Publishing Group, 345 Park Avenue South, New York, NY 10010-1707, USA. Keywords: United States, Tampa, Myelodysplastic Syndrome Immunology, Autoimmune Disease, Autoimmune Disorder, Cancer, Hematology, Hematopoiesis, Immunology, Leukemia, Myelodysplastic Syndromes, Oncology, Therapy, Treatment. This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2009, Biotech Business Week via NewsRx.com.
|
